Senate overwhelmingly approves congressional review in bipartisan show of strength


In a sweeping show of bipartisan support, on Thursday the Senate passed the Iran Nuclear Agreement Review Act – a clear rebuke of the White House’s approach to the Iranian nuclear negotiations and its attempt to exclude Congress. The final count was 98 in favor and one against. Senator Tom Cotton (R-Ark.), the only senator to oppose the bill, asserted that the Iran deal should be “submitted as a treaty,” requiring a two-thirds vote in the Senate. The Iran Nuclear Agreement Review Act would provide Congress an oversight role and would give members 30 days to review a final deal, during which sanctions could not be lifted. Additionally, 65% of Americans believe that any agreement with Iran should be subject to congressional approval, according to a poll released on April 27.

Chairman of the Senate Foreign Relations Committee and co-author of the legislation Senator Bob Corker (R-Tenn.) said, “I think the American people want the United States Senate and the House of the Representatives on their behalf to ensure that Iran is held accountable.” Co-author of the legislation Senator Robert Menendez (D-N.J.), in his speech on the Senate floor, declared, “From the beginning, we fashioned language to ensure that Congress plays a critical role in judging any final agreement.” He continued, “[W]ithout the passage of this legislation, we will have missed an opportunity to send a clear message to Tehran.”

President Barack Obama originally vowed that he would veto legislation relating to the current negotiations with Iran. However, immediately prior to the Senate Foreign Relations Committee vote on the bill on April 14, the White House signaled that the President would be willing to sign it. Following the announcement, Sen. Corker said, “The reason the administration in the last two hours has chosen the path they’re now taking is the number of senators they realized were going to support this legislation.”


Breaking the Silence, an NGO that has recently been in the news for its criticism of Israel’s actions during last summer’s Operation Protective Edge, was explicitly directed by European charities to prove that Israel acted improperly, the watchdog group NGO Monitor showed in a report released Monday.

NGO Monitor’s staff translated the terms of Breaking the Silence’s agreement with OxFam and other organizations. In the case of Oxfam, the agreement called for:

[Breaking the Silence] signed an agreement with Oxfam, a British organization, to conduct interviews with “as many” soldiers as possible who will testify regarding [Israeli] “immoral actions” that violate human rights. In 2009, the British organization donated 74,595 NIS to the organization.

To continue reading, click here for 


Israel didn’t just send medical and rescue staff to Nepal in the wake of the earthquake, it also sent therapeutic clowns. No other country includes medical clowns in its overseas disaster-relief crew. But Israel has blazed a trail in professionalizing clown therapy through the Dream Doctors Project, a privately supported program that oversees 110 trained medical clowns working at 29 hospitals across Israel. Israeli research on professional therapeutic clowns has shown that their inclusion on a medical team has measurable benefits in pain relief, stress reduction and boosting immunity. They are now used in Israel anywhere from adult and children’s wards, to operating rooms, delivery rooms and with sexual abuse victims. Dream Doctors previously joined Israeli relief teams in Thailand, Indonesia and Haiti, says Karin Schneid, project coordinator for the Philnor Foundation, which supports the project. “They’ve developed a unique methodology for working with trauma in disaster zones. They are trained by professionals here in Israel before their missions,” Schneid tells ISRAEL21c. Two Dream Doctors arrived in Nepal on May 2 to assess needs, and another three followed the next day. (via Israel21c)

Be the first to comment

Please check your e-mail for a link to activate your account.